Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
INCB081776 is a dual inhibitor of Axl and Mer that blocks TAM family kinase signaling, which may results in enhanced anti-tumor immunity (Cancer Res 2018;78(13 Suppl):Abstract nr 3759).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|INCB081776||INCB-081776||AXL Inhibitor 29||INCB081776 is a dual inhibitor of Axl and Mer that blocks TAM family kinase signaling, which may results in enhanced anti-tumor immunity (Cancer Res 2018;78(13 Suppl):Abstract nr 3759).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|AXL positive||lung non-small cell carcinoma||unknown||INCB081776||Preclinical - Cell line xenograft||Actionable||In a preclinical study, INCB081776 inhibited Axl phosphorylation in tumor, enhanced anti-tumor immune response, inhibited tumor growth in immunocompetent, but not immunodeficient mouse models of non-small cell lung cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 3759).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03522142||Phase I||INCB081776 INCB081776 + Nivolumab||A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors||Active, not recruiting||USA||4|